'Middle Ground' Avastin Proposal Could Maintain Access for Molecularly Defined Breast Cancer Patients | GenomeWeb

Originally published Aug. 16.

By Turna Ray

In a last-ditch effort to keep Avastin on the market for breast cancer patients, Roche subsidiary Genentech has requested that the US Food and Drug Administration maintain the drug as an option for patients with aggressive disease and limited treatment options — a subset of patients that could include women with a molecularly distinct, triple-negative form of the disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.